NCT05282459View on ClinicalTrials.gov

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

December 3, 2024

Study Completion Date

March 3, 2025

Conditions
LeukemiaLeukemia, MyeloidMonocytic Leukemia
Interventions
DRUG

Enasidenib mesylat dose escalation

Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.

Trial Locations (1)

94305

Stanford Cancer Institute, Palo Alto

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Stanford University

OTHER

NCT05282459 - Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation | Biotech Hunter | Biotech Hunter